Long-term safety and efficacy of tralokinumab in more than 1400 patients with moderate-to-severe atopic dermatitis treated for up to 42 months: An interim analysis of ECZTEND

Authors
Category Primary study
ConferenceBritish Journal of Dermatology
Year 2022
This article has no abstract
Epistemonikos ID: 7df95476b098aee48634ebef663c0da1bcbceeaa
First added on: Apr 30, 2026